Treatment of HBe Antigen-Positive Chronic Hepatitis B

 

 Buy Article Permissions and Reprints

ABSTRACT

Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA in serum (< 1 × 10⁶ copies/mL), and a marked reduction in hepatic inflammation. Licensed antiviral therapies are the interferon (IFN) alphas and the nucleoside analogue lamivudine. Both drugs enhance the rate at which HBeAg seroconversion takes place and thus reduce progression of disease. These therapeutic agents are ineffective if given when there is no ongoing hepatitis (i.e., normal ALT), and their efficacy is greatest in individuals with the most active disease. The effectiveness of these two classes of drugs is similar, and it is possible that the two therapies combined are more effective than monotherapy with either drug. A high side-effect profile and the high risk of further morbidity when given to patients with decompensated disease limit the use of IFN-α. When prescribing lamivudine, drug resistance that increases with duration of therapy and the potential risk of a severe flare of hepatitis with sudden cessation of therapy, probably greatest in patients with cirrhosis, are realistic concerns. Both patient and physician need to recognize the need for close monitoring both during and after cessation of any antiviral therapy for hepatitis B.

REFERENCES

• 1 Scullard G H, Andres L L, Greenberg H B. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside.  Hepatology . 1981;  1 228-232
  PubMedGoogle Scholar
• 2 Lok A, Novick D, Karayiannis P. A randomized study of the effects of adenine arabinoside 5′-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication.  Hepatology . 1985;  5 1132-1138
  PubMedGoogle Scholar
• 3 Hsu Y, Chien R, Yeh C. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology . 2002;  35 1522-1527
  CrossrefPubMedGoogle Scholar
• 4 Martinot-Peignoux M, Boyer N, Colombat M. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers.  J Hepatol . 2002;  36 543-546
  CrossrefPubMedGoogle Scholar
• 5 Wong D, Cheung A, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B.  Ann Intern Med . 1993;  119 312-323
  PubMedGoogle Scholar
• 6 Wong D, Yim C, Nayor D. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.  Gastroenterology . 1995;  108 165-171
  CrossrefPubMedGoogle Scholar
• 7 Perrillo R, Schiff E, Davis D. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B.  N Engl J Med . 1990;  35 295-301
  PubMedGoogle Scholar
• 8 Lin S, Sheen I, Chien R, Chu C, Liaw Y F. Long term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology . 1999;  23 971-975
  PubMedGoogle Scholar
• 9 Yuen M, Hui C, Cheng C. Long term follow up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.  Hepatology . 2001;  34 139-145
  CrossrefPubMedGoogle Scholar
• 10 Lau D, Everhart J, Kleiner D. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.  Gastroenterology . 1997;  113 1660-1667
  PubMedGoogle Scholar
• 11 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S, and the European Concerted Action on Viral Hepatitis (EUROHEP). Long-term outcome of hepatitis B e antigen- positive patients with compensated cirrhosis treated with interferon alfa.  Hepatology . 1997;  26 1338-1342
  CrossrefPubMedGoogle Scholar
• 12 Niederau C, Heintges T, Lange S. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med . 1996;  334 1422-1427
  CrossrefPubMedGoogle Scholar
• 13 Hoofnagle J H, Di Bisgalie M A, Laggoner J H, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to hepatitis B.  Gastroenterology . 1993;  104 1116-1121
  PubMedGoogle Scholar
• 14 Lok A SF, Chung H T, Liu V WS, Ma O CK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa.  Gastroenterology . 1993;  105 1833-1838
  PubMedGoogle Scholar
• 15 Brook M G, Karayiannis P, Thomas H C. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy?.  <~>A statistical analysis of predictive factors. Hepatology . 1989;  10 761-763
  PubMedGoogle Scholar
• 16 Kao J H, Wu N H, Chen P J, Lai M Y, Chen D S. Hepatitis B and the response to interferon therapy.  Hepatology . 2000;  33 998-1002
  CrossrefPubMedGoogle Scholar
• 17 Chu C J, Hussain M, Lok A SF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.  Gastroenterology . 2002;  122 1756-1762
  CrossrefPubMedGoogle Scholar
• 18 Janssen H, Gerken G, Carreno V. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment.  Hepatology . 1999;  30 238-243
  CrossrefPubMedGoogle Scholar
• 19 Carreno V, Marcellini P, Hadziyannis S. Retreatment of chronic hepatitis B e antigen positive patients with recombinant interferon alfa 2a.  Hepatology . 1999;  29 277-282
  CrossrefPubMedGoogle Scholar
• 20 Nevens F, Main J, Honkoop P. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study.  Gastroenterology . 1997;  113 1258-1263
  PubMedGoogle Scholar
• 21 Lai C, Chien R, Leung N. A one year trial of lamivudine for chronic hepatitis B.  N Engl J Med . 1998;  339 61-68
  CrossrefPubMedGoogle Scholar
• 22 Dienstag J, Schiff E, Wright T. Lamivudine as initial treatment for chronic hepatitis B in the United States.  N Engl J Med . 1999;  341 1256-1263
  CrossrefPubMedGoogle Scholar
• 23 Schalm S, Heathcote J, Cianciara J. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial.  Gut . 2000;  46 562-568
  CrossrefPubMedGoogle Scholar
• 24 Liaw Y F, Leung N, Chang T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.  Gastroenterology . 2000;  119 172-180
  CrossrefPubMedGoogle Scholar
• 25 Leung N, Lai C, Chang T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology . 2001;  33 1527-1531
  CrossrefPubMedGoogle Scholar
• 26 Perrillo R P, Lai C L, Liaw Y F. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.  Hepatology . 2002;  36 186-194
  CrossrefPubMedGoogle Scholar
• 27 Chien R, Liaw Y F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B.  Hepatology . 1999;  30 770-774
  CrossrefPubMedGoogle Scholar
• 28 Lewin S R, Ribeiro R M, Walters T. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.  Hepatology . 2001;  34 1012-1020
  CrossrefPubMedGoogle Scholar
• 29 Ahmed S, Tavan D, Pichoud C. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.  Hepatology . 2000;  32 1078-1088
  CrossrefPubMedGoogle Scholar
• 30 Liaw Y F. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.  Antiviral Chem Chemother . 2000;  12 67-71
  PubMedGoogle Scholar
• 31 Yuen M, Sablon E, Hui C. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.  Hepatology . 2001;  34 785-791
  CrossrefPubMedGoogle Scholar
• 32 Buti M, Cotrina M, Valdes A. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?.  J Hepatol . 2002;  36 445-446
  CrossrefPubMedGoogle Scholar
• 33 Liu C, Chen P, Lai M, Kao J, Chen D S. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences.  Hepatology . 2001;  34 583-589
  CrossrefPubMedGoogle Scholar
• 34 Liaw Y F, Chien R, Yeh C, Tsai S, Chu C. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.  Hepatology . 1999;  30 567-572
  CrossrefPubMedGoogle Scholar
• 35 Bonacini M, Kurz A, Locarnini S. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.  Gastroenterology . 2002;  122 244-250
  PubMedGoogle Scholar
• 36 Wong V WS, Chan H, Wong M, Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B?.  J Hepatol . 2002;  36 177
  PubMedGoogle Scholar
• 37 Liaw Y F, Chien R N, Yeh C T, Tsai S L, Chu C M. To continue or not continue lamivudine therapy after emergence of YMDD mutations (Abst 88).  Gastroenterology . 2002;  122 7
  PubMedGoogle Scholar
• 38 Ono-Nita S, Kato N, Shiratori Y. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.  J Clin Invest . 1999;  103 1635-1640
  PubMedGoogle Scholar
• 39 Perrillo R, Schiff E, Yoshida E. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology . 2000;  32 129-134
  CrossrefPubMedGoogle Scholar
• 40 Peters M, Hann H W, Martin P. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses Lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis (Abst 13).  J Hepatol . 2002;  36 6
  PubMedGoogle Scholar
• 41 Torresi J, Earnest-Silveira L, Deliyannis G. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.  Virology . 2002;  293 305-313
  CrossrefPubMedGoogle Scholar
• 42 Yeh C, Chien R, Chu C, Liaw Y F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.  Hepatology . 2000;  31 1318-1326
  CrossrefPubMedGoogle Scholar
• 43 Kim J W, Lee H S, Woo G H. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.  CID . 2001;  33 403-405
  PubMedGoogle Scholar
• 44 Marcellin P, Chang T T, Lim S G. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results (Abst 674).  Hepatology . 2001;  34 340A
  CrossrefPubMedGoogle Scholar
• 45 Yang H, Westland C E, Delaney W E. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.  Hepatology . 2002;  36 464-473
  CrossrefPubMedGoogle Scholar
• 46 Walsh K M, Woodall T, Lamy P. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.  Gut . 2001;  149 436-440
  PubMedGoogle Scholar
• 47 Barbaro G, Zechini F, Pellicelli A. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.  J Hepatol . 2001;  35 406-411
  CrossrefPubMedGoogle Scholar
• 48 Serfaty L, Thabut D, Zoulim F. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.  Hepatology . 2001;  34 573-577
  CrossrefPubMedGoogle Scholar
• 49 Lau G, Tsiang M, Hou J. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese patients: a viral dynamics study.  Hepatology . 2000;  32 394-399
  CrossrefPubMedGoogle Scholar
• 50 van Nunen A, Janssen H, Wolters L. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?.  Antiviral Res . 2001;  52 139-146
  CrossrefPubMedGoogle Scholar
• 51 Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution?.  Hepatology . 2000;  32 430-432
  CrossrefPubMedGoogle Scholar
• 52 Liaw Y F, Tsai S, Chien R, Yeh C, Chu C. Prednisolone priming enhances TH1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.  Hepatology . 2000;  32 604-609
  CrossrefPubMedGoogle Scholar
• 53 Villeneuve J P, Willems B. Treatment of chronic hepatitis B with interferon: long term follow-up.  Can J Gastroenterol . 1996;  10 21-25
  PubMedGoogle Scholar
• 54 Lok A, Chung H, Liu V, Ma O. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa.  Gastroenterology . 1993;  105 1833-1838
  PubMedGoogle Scholar
• 55 Song B, Suh D, Lee H, Chung Y, Lee Y. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.  Hepatology . 2000;  32 803-806
  CrossrefPubMedGoogle Scholar
• 56 Brook M, Petrovic L, McDonald J, Scheuer P, Thomas H. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection.  J Hepatol . 1989;  8 218-225
  PubMedGoogle Scholar
• 57 Suzuki Y, Kumada H, Ikeda K. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection.  J Hepatol . 1999;  30 743-748
  CrossrefPubMedGoogle Scholar
• 58 Rehermann B, Lau D, Hoofnagle J H. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.  J Clin Invest . 1996;  97 1655-1665
  PubMedGoogle Scholar
• 59 Boni C, Bertoletti A, Penna A. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.  J Clin Invest . 1998;  102 968-975
  PubMedGoogle Scholar
• 60 Buti M, Sanchez F, Cotrina M. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.  J Infect Dis . 2001;  183 1277-1280
  CrossrefPubMedGoogle Scholar
• 61 Han D, Kim T, Park S. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence.  Transplantation . 2001;  71 387-394
  PubMedGoogle Scholar
• 62 Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy.  Br J Haematol . 2001;  115 58-62
  CrossrefPubMedGoogle Scholar
• 63 Liao C, Lee C, Wu H. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma.  Br J Hepatol . 2002;  116 166-169
  CrossrefPubMedGoogle Scholar